An observational study in Leigh Syndrome, Leigh Disease and Leigh's Necrotizing Encephalopathy, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Open to participants aged 0 Days to 100 Years. Per ClinicalTrials.gov, last updated 2023-12-01.
Sponsored by The University of Texas Health Science Center, Houston · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Leigh Disease with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Leigh Disease · United States.
Among the 14 studies in Leigh Disease with a site in United States, this one is one of 2 that started in 2015, is one of 6 observational ones, and was the 10th registered.
20 studies on the registry are indexed under Leigh Disease; 9 are open to participants now.
Browse Leigh Disease studies →6 of the 14 studies in Leigh Disease with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 4 wk–115 yrs · Healthy volunteers
Columbia University · Sites in United States, Canada
Healthy volunteers
Sanford Health · Sites in United States
Matthew Demczko · Sites in United States
Ages 6 mo–55 yrs
Columbia University · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Leigh Disease studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 0 Days to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 2
First in 2010; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 35 across the 7 interventional studies, 750 across the 6 observational. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 8 most frequent:
The University of Texas Health Science Center, Houston is the lead sponsor of 899 studies on the registry; 214 are open to participants now.
Of its 174 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.
The University of Texas Health Science Center, Houston has 1 study filed under Leigh Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Leigh Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01803906Columbia UniversityTissue Sample Study for Mitochondrial Disorders | 2026-12 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Leigh Disease with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to develop a database containing clinical and laboratory information for patients with Leigh syndrome. The goal is to provide a greater understanding of Leigh syndrome allowing further characterization of this disease.
Leigh syndrome, also known as juvenile sub-acute necrotizing encephalopathy, is a progressive neurodegenerative disorder associated with dysfunction of mitochondrial oxidative phosphorylation (OXPHOS). First described in 1951 by British neuropsychiatrist Archibald Denis Leigh, the condition has evolved from a post mortem diagnosis to a clinical entity with characteristic radiologic and laboratory findings.
Leigh syndrome is a rare and heterogeneous disease, finding a substantial number of patients to study is difficult. The lack of natural history data in Leigh syndrome and the small number of patients included in clinical reports thus far has limited the ability to fully comprehend the progression of this disease and assess prognostic factors. A Leigh syndrome database will help improve our understanding of this rare disease leading to an improved ability to predict outcomes and/or improve treatment paradigms. Collecting natural history data on Leigh syndrome and integrating this information into a database will be useful in understanding the course of the disease and identifying trends.
People with a diagnosis of Leigh syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All people diagnosed with Leigh syndrome.
Phenotypical characteristics of Leigh syndrome
The goal of this project is to collect longitudinal data on the natural history of Leigh syndrome.
Time frame: 10 years
Started Jun 2015 (actual). Primary completion is estimated for Jun 2030, 180 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Texas Health Science Center, Houston →